Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR (2019) A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol 16:589–604. https://doi.org/10.1038/s41575-019-0186-y

Article  PubMed  PubMed Central  Google Scholar 

Yen YH, Kee KM, Li WF, Liu YW, Wang CC, Hu TH et al (2023) Stationary trend in elevated serum alpha-fetoprotein level in hepatocellular carcinoma patients. Cancers (Basel) 15:1222. https://doi.org/10.3390/cancers15041222

Article  CAS  PubMed  PubMed Central  Google Scholar 

Younossi ZM, Otgonsuren M, Henry L, Venkatesan C, Mishra A, Erario M et al (2015) Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009. Hepatology 62:1723–1730. https://doi.org/10.1002/hep.28123

Article  CAS  PubMed  Google Scholar 

Karim MA, Singal AG, Kum HC, Lee YT, Park S, Rich NE et al (2023) Clinical characteristics and outcomes of nonalcoholic fatty liver disease-associated hepatocellular carcinoma in the United States. Clin Gastroenterol Hepatol 21:670-680.e18. https://doi.org/10.1016/j.cgh.2022.03.010

Article  CAS  PubMed  Google Scholar 

Viganò L, Conci S, Cescon M, Fava C, Capelli P, D’Errico A et al (2015) Liver resection for hepatocellular carcinoma in patients with metabolic syndrome: a multicenter matched analysis with HCV-related HCC. J Hepatol 63:93–101. https://doi.org/10.1016/j.jhep.2015.01.024

Article  PubMed  Google Scholar 

Pais R, Fartoux L, Goumard C, Scatton O, Wendum D, Rosmorduc O, Ratziu V (2017) Temporal trends, clinical patterns and outcomes of NAFLD-related HCC in patients undergoing liver resection over a 20-year period. Aliment Pharmacol Ther 46:856–863. https://doi.org/10.1111/apt.14261

Article  CAS  PubMed  Google Scholar 

Koh YX, Tan HJ, Liew YX, Syn N, Teo JY, Lee SY et al (2019) Liver resection for nonalcoholic fatty liver disease-associated hepatocellular carcinoma. J Am Coll Surg 229:467-478.e1. https://doi.org/10.1016/j.jamcollsurg.2019.07.012

Article  PubMed  Google Scholar 

Pal Chaudhary S, Reyes S, Chase ML, Govindan A, Zhao L, Luther J et al (2023) Resection of NAFLD/NASH-related hepatocellular carcinoma (HCC): clinical features and outcomes compared with HCC due to other etiologies. Oncologist 28:341–350. https://doi.org/10.1093/oncolo/oyac251

Article  PubMed  PubMed Central  Google Scholar 

Conci S, Cipriani F, Donadon M, Marchitelli I, Ardito F, Famularo S, et al, He.RC.O.Le.S Group (2022) Hepatectomy for metabolic associated fatty liver disease (MAFLD) related HCC: propensity case-matched analysis with viral- and alcohol-related HCC. Eur J Surg Oncol 48:103–112. https://doi.org/10.1016/j.ejso.2021.07.015.

Grimaudo S, Pipitone RM, Pennisi G, Celsa C, Cammà C, Di Marco V et al (2020) Association between PNPLA3 rs738409 C>G variant and liver-related outcomes in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 1:935-944.e3. https://doi.org/10.1016/j.cgh.2019.08.011

Article  CAS  Google Scholar 

Yip TC, Lee HW, Chan WK, Wong GL, Wong VW (2022) Asian perspective on NAFLD-associated HCC. J Hepatol 76:726–734. https://doi.org/10.1016/j.jhep.2021.09.024

Article  CAS  PubMed  Google Scholar 

Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, Abdelmalek MF, Caldwell S, Barb D et al (2023) AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology 77:1797–1835. https://doi.org/10.1097/HEP.0000000000000323

Article  PubMed  Google Scholar 

Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK et al (2017) The Eighth edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin 67:93–99. https://doi.org/10.3322/caac.21388

Article  PubMed  Google Scholar 

Everhart JE, Wright EC, Goodman ZD, Dienstag JL, Hoefs JC, Kleiner DE et al (2010) Prognostic value of Ishak fibrosis stage: findings from the hepatitis C antiviral long-term treatment against cirrhosis trial. Hepatology 51:585–594. https://doi.org/10.1002/hep.23315

Article  PubMed  Google Scholar 

Bryer J (2017) TriMatch: propensity score matching of non-binary treatments. Available online at: https://cran.r-project.org/web/packages/TriMatch/

Andrade C (2020) Mean difference, standardized mean difference (SMD), and their use in meta-analysis: as simple as it gets. J Clin Psychiatry 81:20f13681. https://doi.org/10.4088/JCP.20f13681

Article  PubMed  Google Scholar 

Malinchoc M, Kamath PS, Gordon FD, Peine CJ, Rank J, ter Borg PC (2000) A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology 31:864–871. https://doi.org/10.1053/he.2000.5852

Article  CAS  PubMed  Google Scholar 

Doyle DJ, Hendrix JM, Garmon EH (2024) American society of anesthesiologists classification. In: StatPearls [Internet]. StatPearls Publishing, Treasure Island, 17 Aug 2023

Dindo D, Demartines N, Clavien PA (2004) Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 240(2):205–213. https://doi.org/10.1097/01.sla.0000133083.54934.ae

Article  PubMed  PubMed Central  Google Scholar 

Eslam M, Sanyal AJ, George J, Sanyal A, Neuschwander-Tetri B, Tiribelli C et al (2020) MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology 158:1999–2014. https://doi.org/10.1053/j.gastro.2019.11.312.e1

Article  CAS  PubMed  Google Scholar 

Caldwell SH, Crespo DM (2004) The spectrum expanded: cryptogenic cirrhosis and the natural history of non-alcoholic fatty liver disease. J Hepatol 40:578–584. https://doi.org/10.1016/j.jhep.2004.02.013

Article  PubMed  Google Scholar 

Browning JD, Kumar KS, Saboorian MH, Thiele DL (2004) Ethnic differences in the prevalence of cryptogenic cirrhosis. Am J Gastroenterol 99:292–298. https://doi.org/10.1016/j.jhep.2004.02.013

Article  PubMed  Google Scholar 

Li J, Yang HI, Yeh ML, Le MH, Le AK, Yeo YH et al (2021) Association between fatty liver and cirrhosis, hepatocellular carcinoma, and hepatitis B surface antigen seroclearance in chronic hepatitis B. J Infect Dis 224:294–302. https://doi.org/10.1093/infdis/jiaa739

Article  CAS  PubMed  Google Scholar 

Shen HM, Ong CN (1996) Mutations of the p53 tumor suppressor gene and ras oncogenes in aflatoxin hepatocarcinogenesis. Mutat Res 366:23–44. https://doi.org/10.1016/s0165-1110(96)90005-6

Article  PubMed  Google Scholar 

Ng AWT, Poon SL, Huang MN, Lim JQ, Boot A, Yu W et al (2017) Aristolochic acids and their derivatives are widely implicated in liver cancers in Taiwan and throughout Asia. Sci Transl Med 9:eaan6446. https://doi.org/10.1126/scitranslmed.aan6446

Article  CAS  PubMed  Google Scholar 

Wild CP, Miller JD, Groopman JD (2015) Mycotoxin control in low- and middle-income countries. International Agency for Research on Cancer, Lyon

Google Scholar 

Gouas D, Shi H, Hainaut P (2009) The aflatoxin-induced TP53 mutation at codon 249 (R249S): biomarker of exposure, early detection and target for therapy. Cancer Lett 286:29–37. https://doi.org/10.1016/j.canlet.2009.02.057

Article  CAS  PubMed  Google Scholar